Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02858791 · ClinicalTrials.gov registry record
MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 99
- Enrollment target
NCT02858791: Completed study, sponsored by Northwell Health.
NCT02858791 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02858791 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
Study Summary
The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.
Primary Outcome
Assess levels of the proinflammatory cytokine macrophage migration inhibitory factor (MIF) before/after standard exercise challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-12-21 |
What the finished NCT02858791 record still lists
NCT02858791 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02858791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02858791 about?
NCT02858791 is a clinical study titled "MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension". The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.
What is the current status of trial NCT02858791?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2013-02. Estimated completion is 2017-12-21.
Who is sponsoring clinical trial NCT02858791?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia